Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...

The US-developed NOVAVAX vaccine against COVID-19 has been approved Monday by the European Medicines Agency (EMA), thus becoming the fifth drug of its kind to become available at a continental level.

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

These awards were approved by the Compensation C Novavax ... today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax NVAX incurred a fourth-quarter ... A regulatory filing is currently under the FDA’s review seeking full approval for the COVID-19 vaccine, with a final decision expected in April.

The Centers for Disease Control and Prevention and District Health Department No. 10 announce updated COVID-19 vaccine ...

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker. The COVID-19 vaccine company, based in Maryland ...